Evaluation of Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 years eligible for High Dose Therapy: a phase II study of the Intergroup Francophone Myeloma (IFM)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Granulocyte colony stimulating factor stimulants
- Indications Multiple myeloma
- Focus Therapeutic Use
- 09 Nov 2020 Status changed from completed to discontinued due to negatives results.
- 28 Sep 2020 Status changed from active, no longer recruiting to completed.
- 10 Dec 2019 Primary endpoint (rate of stringent complete response) has not been met.